Who are 123I-meta-iodobenzylguanidine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ga-68-DOTATOC, Rubidium-82, strontium-89, 18F-rhPSMA-7.3, PET Scan with [18F] VAT, Copper Cu 64 Dotatate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/123i-meta-iodobenzylguanidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

123I-meta-iodobenzylguanidine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

123I-meta-iodobenzylguanidine (123I-meta-iodobenzylguanidine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiopharmaceutical; diagnostic imaging agent. Area: Oncology; Nuclear Medicine; Endocrinology.

phase 3 Radiopharmaceutical; diagnostic imaging agent Norepinephrine transporter (NET) Oncology; Nuclear Medicine; Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

123I-meta-iodobenzylguanidine (123I-meta-iodobenzylguanidine) — Vancouver Coastal Health. 123I-meta-iodobenzylguanidine is a radiolabeled imaging agent that accumulates in neuroendocrine tumors and the sympathetic nervous system, allowing visualization via nuclear scintigraphy.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
123I-meta-iodobenzylguanidine TARGET	123I-meta-iodobenzylguanidine	Vancouver Coastal Health	phase 3	Radiopharmaceutical; diagnostic imaging agent	Norepinephrine transporter (NET)
Ga-68-DOTATOC	Ga-68-DOTATOC	Weill Medical College of Cornell University	marketed	Radiopharmaceutical	Somatostatin receptors (SSTRs) on neuroendocrine tumor cells
Rubidium-82	Rubidium-82	Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)	marketed	PET radiopharmaceutical	Na+/K+-ATPase pump (myocardial uptake mechanism)
strontium-89	strontium-89	Alberta Health services	marketed	Radiopharmaceutical; bone-seeking radioisotope	Hydroxyapatite in bone matrix; osteoblast uptake
18F-rhPSMA-7.3	18F-rhPSMA-7.3	Hackensack Meridian Health	marketed	PET imaging agent / radiopharmaceutical	PSMA (prostate-specific membrane antigen)
PET Scan with [18F] VAT	PET Scan with [18F] VAT	Stony Brook University	marketed	PET imaging agent / Radiopharmaceutical	Vascular adhesion molecules (VAM)
Copper Cu 64 Dotatate	Copper Cu 64 Dotatate	Vanderbilt-Ingram Cancer Center	marketed	Radiopharmaceutical; somatostatin receptor agonist imaging agent	Somatostatin receptor 2 (SSTR2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiopharmaceutical; diagnostic imaging agent class)

Vancouver Coastal Health · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 123I-meta-iodobenzylguanidine — Competitive Intelligence Brief. https://druglandscape.com/ci/123i-meta-iodobenzylguanidine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab